Navigation Links
Adheris Inc. Files For Preliminary Injunction To Stop U.S. Government From Infringing On Constitutionally Protected Speech
Date:9/6/2013

ncellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties;  the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development
'/>"/>
SOURCE inVentiv Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Perrigo Files Registration Statement On Form S-4 In Connection With Proposed Acquisition Of Elan
2. Cell Therapy - Technologies, Markets and Companies - Updated 2013 with New Companies and Profiles
3. Steven Zecola Files a Citizens Petition with the FDA for a New Approach to Address Metastatic Cancer
4. Cellular Dynamics International Files Registration Statement for Proposed Initial Public Offering
5. Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against Dr. Yamanaka for Deception
6. Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against 2012 Nobel Laureate Dr. Yamanaka for Deception
7. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2012
8. Early Stage Drug Delivery Technologies: 62 Profiles of Start-ups and Emerging Companies
9. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
10. TNI BioTech Files Form 10 with SEC
11. Marrone Bio Innovations Files Patent for a Unique Bacillus Species
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) focuses ... at its mid-Atlantic late-phase research facility, located in ... the idea of closing patient disparities in mind. ... advances," said Continental's CEO, Saleh Stevens . ... cell line of Henrietta Lacks, dubious ethical practices ...
(Date:11/24/2014)... Senior Vice President, General Manager ... skills, business acumen Elsevier , a ... and services, congratulates Diane Bartoli , Senior Vice ... Elsevier Clinical Solutions, for being recognized in the 13 ... issue of Profiles in Diversity Journal ® ...
(Date:11/22/2014)... November 21, 2014 Prominent academics, ... will gather on December 3rd at Genetic Rx, ... series. GeneticRx will take place at the Joseph ... and will discuss the present and future of ... skipping, and gene editing—as well as the treatment ...
(Date:11/22/2014)... The “Chiral Chromatography Columns Market by type ... Plastic), by Application [GC, LC (HPLC, UHPLC, Flash ... analyses and studies the major market drivers, restraints, ... and Rest of the World. , Browse 90 ... 135 pages and in-depth TOC on “Chiral Chromatography ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... and WILMINGTON, Del., Sept. 22 For,his lifetime commitment ... of,radiation and other environmental exposures on the developing fetus ... education, Robert,L. Brent, MD, PhD, will be honored as ... for Excellence in Children,s Health Care by Nemours,one of ...
... Preclinical Research at Upcoming Conferences, CALGARY, Sept. ... ONCY) today announced the participation of five of ... conferences,through November 15, 2008 covering clinical trial results ... time for Oncolytics as we begin to share ...
... Names Industry Veteran as Executive Director, INDIANAPOLIS, ... management, clinical, and pharmaceutical testing facility,is announcing the ... industry veteran to lead the division. AIT has ... of West Lafayette-based,Bioanalytical Systems, Inc. (Nasdaq: BASI ...
Cached Biology Technology:Robert L. Brent, MD, PhD, Honored with 2008 Alfred I. duPont Award for Excellence in Children's Health Care 2Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial 2Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial 3AIT Laboratories Expands Pharma Services 2AIT Laboratories Expands Pharma Services 3
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... microcontroller (MCU) and touch technology solutions, today launched the ... with the widest V cc range from ... accuracy and faster I 2 C bus communication speeds, ... EEPROM memory making them ideal for consumer, industrial, computer, ...
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... 2012 Chemicals in the environment that mimic estrogen ... animals. New research to be presented at the 2012 ... in Madison, Wisconsin, reveals that these substances may act ... stages of embryonic development. Estrogenic compounds in the ...
... Autism Speaks, the world,s leading autism science and advocacy ... totaling nearly $2.9 million in funding to support autism ... Speaks, not only for funding research projects which have ... said Autism Speaks Co-founder Bob Wright, "but in supporting ...
... Mich.A dry spring in portions of the Midwest is expected ... on record in 2012, according to a University of Michigan ... 2012 Gulf of Mexico dead zone of about 1,200 square ... forecast is correct, 2012 would replace 2000 (1,696 square miles) ...
Cached Biology News:Environmental estrogens affect early developmental activity in zebrafish 2Environmental estrogens affect early developmental activity in zebrafish 3Autism Speaks awards nearly $2.9 million to fund autism research 2Autism Speaks awards nearly $2.9 million to fund autism research 3Autism Speaks awards nearly $2.9 million to fund autism research 4U-M forecasters predict second-smallest Gulf of Mexico 'dead zone' 2U-M forecasters predict second-smallest Gulf of Mexico 'dead zone' 3U-M forecasters predict second-smallest Gulf of Mexico 'dead zone' 4
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
Biology Products: